Breast cancer: conservative use of ovarian suppression advised for young Asian women

  • Yeo W & al.
  • Breast Cancer Res Treat
  • 4 Jul 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • The Asian Breast Cancer Cooperative Group 2019 issued a new consensus and position paper on ovarian function suppression (OFS) for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BCa).
  • The guidance is more conservative on the use of OFS than near universal use recommended by the European School of Oncology and European Society for Medical Oncology.

Why this matters

  • Premenopausal Asian women have seen dramatic growth in BCa incidence and younger age at peak incidence than Western women.
  • Guidance is needed because of the absence of clinical trials with Asian women.

Study design

  • A 12-member committee reported consensus when there was a ≥75% majority.
  • A literature review was provided.
  • Funding: Novartis.

Key consensus points

  • More trials of endocrine therapy in premenopausal women are needed.
  • Early HR+/HER2 breast cancer: 
    • Not all premenopausal women need adjuvant OFS.
    • Specific clinical factors should guide OFS prescribing, including subpopulation results of SOFT and TEXT clinical trials showing that patients with low progesterone receptor expression and/or high Ki-67 expression obtain greater absolute benefit from OFS.
    • High-risk patients (high recurrence score) who remain premenopausal after adjuvant chemotherapy should be treated with OFS+aromatase inhibitor rather than tamoxifen, despite no clear overall survival benefit.
  • No consensus was reached on preferred modality for OFS.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.